In brief: Rockeby, C3, Heartware

By Staff Writers
Friday, 04 March, 2005

Rockeby Biomed Limited (ASX:RBY) is poised to launch its Candia5 candidiasis diagnostic in Europe, having received ISO certification and CE Mark approval for the product.

Clinical Cell Culture (C3, ASX:CCE) has notched up the first commercial sale of spray-on-skin technology, ReCell, to its Japanese distributor and the announced the first use of ReCell in Japan. C3 Chief Executive Officer Troels Jordansen said the company had invoiced over AUD$400,000 in the first quarter of the calendar year in Japan.

HeartWare (ASX:HTW) has appointed corporate lawyer David McIntyre as chief financial officer and company secretary.

Content from other channels on our network

Testing beef trim sampling cloths for Escherichia coli O157:H7, STEC, and Salmonella species with harmonised enrichments

PhD opportunity in functional snack food innovation

Aseptic, minimal processing and flexible lines on show in 2027

Breaking the biofilm shield that harbours foodborne pathogens

Second cell-cultured food under assessment by FSANZ

Detoxifying 'super fungi' may recover critical minerals

Training centre opens to improve alloy lifecycle

Water utilities know where AI fits — but can the foundations carry it?

FIFA World Cup to generate 156 tonnes of plastic waste

Collaboration provides NZ's largest smart water meter upgrade

Siemens announces AI-enabled software grant to UniSC

Deakin University launches metal resources research centre

Dragos introduces OT-native cybersecurity AI

Construction begins on south‍-‍west WA advanced manufacturing hub

Newcastle carbon capture plant opens

In brief: Rockeby, C3, Heartware

Australia's first cases of H5 avian influenza confirmed

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Content from other channels on our network